Italia markets closed

CTMX Jun 2024 5.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
3,52000,0000 (0,00%)
Alla chiusura: 12:25PM EDT
Schermo intero
Chiusura precedente3,5200
Aperto3,5200
Denaro3,1000
Domanda6,0000
Prezzo d'esercizio5,00
Scadenza2024-06-21
Min-Max giorno3,5200 - 3,5200
Contratto - Min-MaxN/D
Volume5
Open Interest247
  • GlobeNewswire

    CytomX Therapeutics to Present at Upcoming September Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in September. H.C. Wainwright 25th Annual Global Investment Conference Date: Tuesday, September 12, 2023 Company Presentation: 11:30 a.m. ET Location: New York, NY Cantor Global Healthcare Conference Date: Tuesday, September 26, 2023 Fi

  • GlobeNewswire

    CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the H.C. Wainwright Immune Cell Engager Virtual Conference on Thursday, August 17 at 9:00 a.m. ET. A live webcast of the fireside chat will be available on the Events and Presentations page of CytomX’s website at www.cytomx.c

  • GlobeNewswire

    CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

    - CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 - - IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) anticipated in the fourth quarter of 2023 - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported second quarter 2023 fin